List of Tables
National Institutes of Health, Pharmaceuticals & Healthcare, Key Facts 2
National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
National Institutes of Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22
National Institutes of Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23
National Institutes of Health, Deals By Therapy Area, 2011 to YTD 2017 24
National Institutes of Health, Medical Devices Deals, 2011 to YTD 2017 26
National Institutes of Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 27
Aura Biosciences Secures An Additional US$3 Million In Series A Financing 40
BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 41
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 42
Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 43
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 44
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 45
SillaJen Enters into R&D Agreement with National Cancer Institute 46
Xcovery Partners with National Cancer Institute and Children’s Oncology Group 47
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 48
Race Oncology Enters into Agreement with National Cancer Institute 49
Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 50
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 51
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 52
Pandomedx Enters Into Collaboration with National Cancer Institute 53
DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 54
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 55
Oncoceutics Enters into Research Agreement with National Institutes of Health 56
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 57
Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 58
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 59
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 60
Agenus Enters into Agreement with National Cancer Institute 61
Threshold Pharma Enters into Agreement with National Cancer Institute 62
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 63
Immunovia to Enter into Agreement with National Cancer Institute 64
Pfizer Enters into Agreement with National Cancer Institute 65
Epizyme Enters into Research Agreement with National Cancer Institute 66
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 67
Atrin Pharma Enters into Agreement with National Cancer Institute 68
Riptide Bioscience Enters into Agreement with National Cancer Institute 69
PapGene Enters into Agreement with National Cancer Institute 70
Cellerant Therapeutics Enters into Contract with National Institutes of Health 71
Cellectar Biosciences Enters into Contract with National Cancer Institute 72
University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 73
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 74
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 75
RedHill Biopharma Enters into Agreement with NIAID 76
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 77
Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 78
Kite Pharma Enters into R&D Agreement with National Cancer Institute 79
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 80
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 81
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 82
Eagle Pharma Enters into Agreement with National Institutes of Health 83
Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 84
PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 85
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 86
Regen BioPharma Enters into Research Agreement with National Institutes of Health 87
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 88
OriGene Technologies Enters into Contract with National Cancer Institute 89
SolaranRx Enters into R&D Agreement with National Cancer Institute 90
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 91
Precision Biologics Enters into R&D Agreement with National Cancer Institute 92
Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 93
GlaxoSmithKline Enters into Research Agreement with NIAID 94
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 95
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 96
Saint Louis University Enters into Agreement with National Institutes of Health 97
SRI International Enters into Biological Testing Facility Contract with NICHD 98
KIYATEC Enters into Research Contract with National Cancer Institute 99
Protein Foundry Enters into Research Contract with NHLBI 100
SuviCa Enters into Contract with National Cancer Institute 101
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 102
Galena Biopharma Enters into Agreement with National Cancer Institute 103
Dimension Therapeutics Enters into R&D Agreement with Eunice Kennedy Shriver National Institute 104
WiCell Research Institute Enters into Distribution Agreement with NHLBI 105
Etubics Enters into R&D Agreement with National Cancer Institute 106
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 107
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 108
FirstString Research Enters into R&D Agreement with NCATS 109
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 110
GenVec Enters into Research Agreement with LMIV 111
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 112
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 113
Intrexon Enters into R&D Agreement with National Cancer Institute 114
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 115
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 117
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 118
MedImmune Enters into Co-Development Agreement with National Cancer Institute 119
Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 120
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 121
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 122
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 123
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 124
Kadmon Enters into R&D Agreement with NIDCR 125
Foamix Enters into Co-Development Agreement with National Eye Institute 126
New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 127
Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 128
Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 129
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 130
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 131
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 132
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 133
Nanobiotix Enters Into Co-Development Agreement With National Cancer Institute For NBTX-IV 134
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 135
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 136
National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 137
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 138
Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 140
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 141
Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 142
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 143
Delcath Systems Extends Co-Development Agreement With National Cancer Institute 144
FEI Enters Into R&D Agreement With NIH 145
DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 146
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 147
Concert Pharma Enters Into Research Agreement With NIH 149
AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 150
BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 151
Afraxis Enters Into Co-Development Agreement With National Institutes of Health 152
Aura Biosciences Enters Into Research And Development Agreement With NIH 153
Lion Biotech Amends Co-Development Agreement with National Cancer Institute 154
Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 155
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 156
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 158
GNS Healthcare Enters Into An Agreement With National Cancer Institute 159
Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 160
New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 161
RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 162
Salubris Biotherapeutics to Enter into Licensing Agreement with National Institutes of Health 163
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 164
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 166
PaxVax Enters into Licensing Agreement with National Institutes of Health 167
ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 168
Medigen Vaccine Biologics Expands Licensing Agreement with National Institutes of Health for Dengue Vaccine 169
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 170
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 171
Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 172
Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 173
Elixirgen Enters into License Agreement with National Institute on Aging 174
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 175
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 177
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 178
JSK Therapeutics Enters Into Licensing Agreement with NIH Office of Technology Transfer 179
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 180
Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 181
Lion Biotech Amends Licensing Agreement with National Institutes of Health 182
Biologics Resources Enters into Licensing Agreement with National Institutes of Health 183
uniQure Amends Licensing Agreement with National Institutes of Health for AAV5 Products 184
Microbiotix Receives Notice for Exclusive Patent License from National Institutes of Health 185
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 186
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 187
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 188
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 189
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 190
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 192
Peptron Enters into Licensing agreement with National Institutes of Health 193
KannaLife Sciences Enters Into Licensing Agreement With NIH 194
Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 195
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 196
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 197
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 198
Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 199
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 200
KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 201
BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 202
BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 203
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 204
Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 205
National Institutes of Health, Key Competitors 206
National Institutes of Health, Key Employees 207
National Institutes of Health, Subsidiaries 208
National Institutes of Health-製薬・医療分野：企業M&A・提携分析 |
◆英語タイトル：National Institutes of Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013602
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：810
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
【レポートの概要】
◆商品コード：DATA8013602
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：810
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
| Single User | USD250 ⇒換算￥37,000 | 見積依頼/購入/質問フォーム |
| Site License（同一事業所内共有可） | USD500 ⇒換算￥74,000 | 見積依頼/購入/質問フォーム |
| Enterprisewide License（複数事業所内共有可） | USD750 ⇒換算￥111,000 | 見積依頼/購入/質問フォーム |
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
National Institutes of Health (NIH) a subsidiary of U.S. Department of Health and Human Services is a biomedical research institute that discovers and develops research strategies for the improvement of health. The institute’s medical research initiatives includes environmental influence on the child health outcomes, NIH common fund, cancer prevention and detection; collaboration in support of research on the nervous system; data science at NIH, precision medicine initiative cohort program, the brain initiative, and others. It also offers training and education program in intramural, extramural, disease prevention, and clinical research training and medical education. The institute offers funding for various types of grants, contracts, and programs that help repay loans for researchers. NIH is headquartered in Bethesda, Maryland, the US.
National Institutes of Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
【レポートの目次】
| ★海外企業調査レポート[National Institutes of Health-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら |
